Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, September 2001, p. 2571-2576, Vol. 45, No. 9
Department of Pharmaceutical Chemistry,
University of California, San Francisco, California 94143-0446
Received 13 February 2001/Returned for modification 2 April
2001/Accepted 18 June 2001
Parasitic protozoa lack the ability to synthesize purine
nucleotides de novo, relying instead on purine salvage enzymes for their survival. Guanine phosphoribosyltransferase (GPRT) from the
protozoan parasite Giardia lamblia is a potential target
for rational antiparasitic drug design, based on the experimental evidence, which indicates the lack of interconversion between adenine
and guanine nucleotide pools. The present study is a continuation of
our efforts to use three-dimensional structures of parasitic phosphoribosyltransferases (PRTs) to design novel antiparasitic agents.
Two micromolar phthalimide-based GPRT inhibitors were identified by
screening the in-house phthalimide library. A combination of
structure-based scaffold selection using virtual library screening across the PRT gene family and solid phase library synthesis led to
identification of smaller (molecular weight, <300) ligands with
moderate to low specificity for GPRT; the best inhibitors, GP3 and GP5,
had Ki values in the 23 to 25 µM range. These results represent significant progress toward the
goal of designing potent inhibitors of purine salvage in
Giardia parasites. As a second step in this process,
altering the phthalimide moiety to optimize interactions in the
guanine-binding pocket of GPRT is expected to lead to compounds with
promising activity against G. lamblia PRT.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.9.2571-2576.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Virtual Screening of Combinatorial Libraries across
a Gene Family: in Search of Inhibitors of Giardia
lamblia Guanine Phosphoribosyltransferase

*
Corresponding author. Mailing address: Department of
Pharmaceutical Chemistry, 513 Parnassus Ave., Box 0446, University of California, San Francisco, CA 94143-0446. Phone: (415) 476-1321. Fax:
(415) 476-3382. E-mail: ccwang{at}cgl.ucsf.edu.
Present address: Vertex Pharmaceuticals Inc., Cambridge, MA 02139.
This article has been cited by other articles:
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»